Lavipharm S.A (LAVI) — Strategic Asset Allocation Index
Lavipharm S.A (LAVI) has a Strategic Asset Allocation Index of 40.4% as of June 2023. Strategic assets (PP&E of €17.20 Million plus long-term investments of €-) total €17.20 Million, measured against net assets of €42.53 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Lavipharm S.A Strategic Asset Allocation Index (2022–2022)
This chart shows how Lavipharm S.A's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of June 2023, the index stands at 40.4%, representing strategic assets of €17.20 Million against net assets of €42.53 Million EUR. Explore Lavipharm S.A cash conversion from operations to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Lavipharm S.A (2022–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Lavipharm S.A from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Lavipharm S.A market cap and net worth.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 42.3% | €17.06 Million | €17.06 Million | €- | €40.28 Million | — |